Amgen ($AMGN) announced Phase 3 trial results showing that combining Imdelltra with Imfinzi reduced the risk of death by 58% in patients with small-cell lung cancer, compared with Imfinzi alone.…
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
